Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
Status:
Withdrawn
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is determine the optimal dose and schedule of Fusilev to prevent or
reduce Mucositis in patients with Non-Hodgkin's Lymphoma receiving Folotyn treatment.